Forward Looking Statements

Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Introduction and History

- Sirona Biochem was founded in 2009
- TFChem was acquired in 2011

Sirona Biochem (Parent Company)
Vancouver, BC, Canada

TFChem (Wholly Owned Subsidiary)
Cosmetic Valley, France
Sirona’s Fluorination Chemistry Technology
The Solution to Unstable Carbohydrate Molecules

Carbohydrate molecules are unstable by nature
Our technology stabilizes carbohydrate molecules

Resulting in improved bioavailability and selectivity that translates into better safety and efficacy
Investment Highlights

• Sirona Biochem has developed the safest most effective skin lightening agent in the world
  o We are in partnership discussions with five global corporations

• Our family of novel glycoproteins has multiple revenue generating opportunities in anti-aging and regenerative medicine
  o We are in partnership discussions with four global corporations

• Our technologies are currently partnered with Valeant/Obagi and Fosun/Wanbang
# Current Collaborations & Pipeline

## Cosmetic Products

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound</th>
<th>Partnering Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin lightening</td>
<td>SBM-TFC-849</td>
<td>Valeant</td>
</tr>
<tr>
<td>Skin lightening</td>
<td>SBM-TFC-1067</td>
<td>In partnering discussions</td>
</tr>
<tr>
<td>Cell Preservation</td>
<td>SBM-TFC-837</td>
<td>Undergoing testing</td>
</tr>
</tbody>
</table>

## Pharmaceutical Products

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound</th>
<th>Partnering Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>SBM-TFC-039</td>
<td>Fosun in China&lt;br&gt;<strong>Ready for licensing in ROW</strong></td>
</tr>
<tr>
<td>Regenerative Medicine</td>
<td>SBM-TFC-1165</td>
<td>Undergoing testing</td>
</tr>
<tr>
<td>Inflammatory Disease</td>
<td>SBM-TFC-1227</td>
<td>JV with Bloom Burton &amp; Co</td>
</tr>
</tbody>
</table>
Leading Cosmetic and Pharmaceutical Companies

- Allergan
- Estée Lauder
- P&G
- gsk
- Chanel
- Pfizer
- L'Oréal
- LVMH
- Moët Hennessy, Louis Vuitton
- Pierre Fabre
- AmorePacific
- Shiseido
- Galderma
Global Skin Lightening Market

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>12.8</td>
<td>13.2</td>
<td>13.7</td>
<td>14.1</td>
</tr>
<tr>
<td>Asia-Pacific</td>
<td>4.1</td>
<td>4.5</td>
<td>4.8</td>
<td>5.2</td>
</tr>
<tr>
<td>US, EU, ROW</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
<td>0.5</td>
</tr>
</tbody>
</table>
Skin Lightening Agent

SBM-TFC-1067

ADVANCING CHEMISTRY. ENHANCING HEALTH.
The Problem

Deoxyarbutin and arbutin are the most widely used skin-lightening agents. However, they have safety risks associated with their use.

- Deoxyarbutin is a tyrosinase inhibitor that prevents melanin formation
- Deoxyarbutin is unstable and is broken down in the body, releasing hydroquinone, a known carcinogen
- Hydroquinone is banned in the EU & Korea, restricted in the US, undergoing regulatory scrutiny in the Asia Pacific markets
Our goal was to develop a safer and more effective compound than Deoxyarbutin.
We have successfully developed a stabilized Deoxyarbutin, with zero hydroquinone released, thus eliminating potential adverse events.

Superior safety and 8 times the efficacy of deoxyarbutin.
Safety of SBM-TFC-1067

In vitro stability: percentage of hydroquinone released

SBM-TFC-1067 is stable and extremely safe, with zero hydroquinone released in all tested conditions (chemical, biological).
Efficacy of SBM-TFC-1067

Inhibition of Human Tyrosinase (300U/ml)

SBM-TFC-1067 has 8 times the efficacy of deoxyarbutin
Safety and Efficacy Summary

**Safety**

- Superior safety profile over deoxyarbutin with zero hydroquinone released
- No genotoxicity (0-0.25%)
- Very minor ocular irritation at 0.14%
- No ocular irritation at 0.01%
- No skin irritation at 0.05%
- No sensitization
- No phototoxicity

**Efficacy**

- 8 times the efficacy of deoxyarbutin
- High flux capacity to the site of action in the epidermis
- Antioxidant properties
Synthesis of SBM-TFC-1067 and Patents

• The synthesis of SBM-TFC-1067 is only a three step process
• Scale-up and manufacturing is straightforward and can be done at any CRO
• A highly favourable cost of goods (Estimate: $0.10 for the active in 100ml final formulation)
• Patent: PCT application on 04/03/2015: PCT/FR2015/050530
Glycoprotein Program
Anti-Aging and Regenerative Medicine
Natural Anti-Freeze Glycoproteins (AFGPs)

...enable survival under freezing temperatures
At the conclusion of a 12 day study, 100% of the unprotected cells were dead whereas 75% of the glycoprotein-protected cells were fully viable.

**Efficacy of SBM-TFC-837**

SBM-TFC-837 protects fibroblasts from the stressed condition of serum deprivation
Efficacy of SBM-TFC-837

Viability of fibroblasts after UV irradiation (11J/cm²)

SBM-TFC-837 protects fibroblasts from the stressed condition of UV irradiation.
Synthesis and Patents

• Family of compounds with a carbohydrate and 1 to 3 amino acids

Sirona’s Glycoprotein program: Biomimicry

The potential opportunities are enormous

Sirona’s Glycoprotein program

Cosmetic Active Ingredients
- Anti-aging
- Protection & Regeneration
  - Healing, Wound care, Hypothermic protection, Sunscreen
  - Post-sunburn/radiotherapy

Adjuvants for biological material preservation
- Cells
  - Stem cells
  - Islet cells
  - Platelets
  - Red blood cells
  - Adipocytes
- Tissues
  - Skin explants, RHE, Cornea
- Organs
  - Transplant
  - Renal Reperfusion
- Living organisms
  - Vaccines
SGLT2 Inhibitor Program
Type 2 diabetes
More than 371 million people have diabetes.

By 2030, this will rise to 552 million.

In 2011, 4.8 million people died due to diabetes and more than $471 billion US was spent on related healthcare.

Global prevalence is drastically increasing.
Emerging Markets
India & China Outpacing the USA

By 2030, experts predict that Type 2 Diabetes will grow by:
US 25%, India 66%, and China 44%
The novel mechanism of action for SGLT2 inhibition is blocking the re-uptake of glucose from the kidneys and improving the obesity profile.
Head-to-Head Trial

- Six hours after administration, SBM-TFC-039 reduced blood glucose by 44% compared to 26% for Canagliflozin.
- SBM-TFC-039 (1 mg/kg) proved to be more efficacious than Canagliflozin.
Results of the 14 Day Toxicology Study

- Efficacy study dosing: 3 mg/kg/day
- Pharmacokinetics study dosing: 10mg/kg/day PO and 1 mg/kg/ day IV
## SBM-TFC-039 Ongoing Development

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upfront payment</td>
<td>Complete</td>
</tr>
<tr>
<td>Preclinical Studies (first line tests)</td>
<td></td>
</tr>
<tr>
<td>• Urinary Glucose Excretion (UGE)</td>
<td>Complete (06/2014)</td>
</tr>
<tr>
<td>• Oral glucose tolerance test (OGTT)</td>
<td>Complete (06/2014)</td>
</tr>
<tr>
<td>• Pharmacokinetic study in rats</td>
<td>Complete (07/2014)</td>
</tr>
<tr>
<td>• Batch production of 80g of compound</td>
<td>Complete (12/2014)</td>
</tr>
<tr>
<td>• 14 day toxicology study with repeated administration in Sprague Dawley (SD) rats</td>
<td>Complete (02/2015)</td>
</tr>
<tr>
<td>Milestone payment for completion of toxicology study</td>
<td>Expected in March 2016</td>
</tr>
<tr>
<td>Preclinical studies (second line tests)</td>
<td></td>
</tr>
<tr>
<td>Investigational New Drug (IND)</td>
<td></td>
</tr>
</tbody>
</table>
# Revenue Generating Opportunities*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Successful licensing of 1067</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Assumes exclusive worldwide rights</td>
<td>• 1067 is not licensed to a major corporation.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Peak penetration at year 10 = 15%.</td>
<td>• Unfavorable testing results.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• 10 year sales period from 2019 to 2028. (20 year patent protection).</td>
<td>• Change in business priority of potential partner.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>** Please see next slide for comparable transactions</td>
<td>• Merger or acquisition of a potential partner creates unexpected delays.</td>
</tr>
<tr>
<td>Commercialization of 849</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Assesses active ingredient is utilized in existing formulations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Licensing agreement ($9.5M + royalties) Wanbang/Fosun</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>These milestone payments are according to the licensing agreement.</td>
<td>• Chemical processes and scale-up are not economically viable.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Delays in commercialization.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Unfavorable testing results</td>
</tr>
<tr>
<td>Glycoprotein collaboration yields licensing agreement with cosmetic / pharma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• First line tests by Wanbang are not acceptable to them.</td>
</tr>
<tr>
<td>partner</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Change in business priority</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The sole purpose of the forward looking information is to show the potential revenue generation from milestones achieved for the noted compounds/products if same were achieved. The potential revenue shown is not a forecast but solely a target for Sirona management.
Comparable Transactions

- Average dermatology royalty rates = 17.7%
- Medicis Pharmaceuticals acquired the Esoterica skin care product line from SmithKline Beecham Consumer Brands for $9.2 million in 1991 (UK & US territories only).
- Medicis Pharmaceuticals obtained exclusive worldwide rights for the development and commercialization of an investigational drug targeted at certain topical skin applications in March, 2012. Medicis paid an up-front payment of $25.0 million, an additional $80.0 million upon the achievement of certain research, development and regulatory milestones and up to an additional $120.0 million upon the achievement of certain commercial milestones, as well as royalties on future sales. The total deal value was $225 million.
- Valeant Pharmaceuticals acquired Medicis Pharmaceuticals in December 2012 for $44.00 per share in cash. The transaction was valued at approximately $2.6 billion.
- All values mentioned above are in US currency.

Source: Informa’s Medtrack
Peer Group

Source: First Berlin

TSX-V: SBM
Sirona Biochem vs the Nasdaq Biotechnology Index

NBI +0.22%
SBM +33%
Share Capital

Shares Issued & O/S: 156,695,048
Stock Options 14,340,000
Warrants - $0.20 strike exp 03/06/2017 9,245,970
Shares Issued (Fully Diluted): 180,281,018
Market Cap $31,339,000
Cash $1,160,000

(As at Jan 31/16)
Who we are

Howard J. Verrico, MD
CEO and Chairman of the Board

Geraldine Deliencourt-Godefroy, PhD
Chief Scientific Officer

Christopher Hopton, CGA
Chief Financial Officer

Michelle Seltenrich, MBA, BSc
VP, Operations

Attila Hajdu, MBA, MSc
Chief Business Development Officer

TSX-V: SBM
Summary

• Sirona Biochem is a discovery and development stage biotechnology company that is the leader in commercializing carbohydrate chemistry

• There are significant upside investment opportunities following the successful:
  o Licensing of our skin lightener
  o Licensing of our glycoprotein for anti-aging and regenerative medicine
  o Licensing of our SGLT2 inhibitor for type 2 diabetes